Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1992 3
1995 2
1996 2
1997 2
1998 1
2003 2
2005 1
2006 1
2008 1
2009 1
2010 2
2011 1
2012 3
2013 2
2014 2
2015 4
2016 1
2017 1
2018 1
2019 1
2021 1
2022 1
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Burris HA 3rd, et al. Among authors: modiano mr. J Clin Oncol. 1997 Jun;15(6):2403-13. doi: 10.1200/JCO.1997.15.6.2403. J Clin Oncol. 1997. PMID: 9196156 Clinical Trial.
Ocular toxic effects of fenretinide.
Modiano MR, Dalton WS, Lippman SM, Joffe L, Booth AR, Meyskens FL Jr. Modiano MR, et al. J Natl Cancer Inst. 1990 Jun 20;82(12):1063. doi: 10.1093/jnci/82.12.1063. J Natl Cancer Inst. 1990. PMID: 2140863 Free article. No abstract available.
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Burris HA 3rd, et al. Among authors: modiano mr. J Clin Oncol. 2023 Dec 20;41(36):5482-5492. doi: 10.1200/JCO.22.02777. J Clin Oncol. 2023. PMID: 38100992 Clinical Trial.
Cancer in Hispanics: issues of concern.
Modiano MR, Villar-Werstler P, Meister J, Figueroa-Vallés N. Modiano MR, et al. J Natl Cancer Inst Monogr. 1995;(18):35-9. J Natl Cancer Inst Monogr. 1995. PMID: 8562220 Review.
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. Zinner RG, et al. Among authors: modiano mr. J Thorac Oncol. 2015 Jan;10(1):134-42. doi: 10.1097/JTO.0000000000000366. J Thorac Oncol. 2015. PMID: 25371077 Free PMC article. Clinical Trial.
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA. Sequist LV, et al. Among authors: modiano mr. Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11. Oncologist. 2019. PMID: 30975923 Free PMC article. Clinical Trial.
35 results